article · Expert Review of Vaccines
High levels of population immunity suggest that the acute phase of the SARS-CoV-2 pandemic is likely drawing to a close. Although novel variants and sublineages capable of evading antibody responses will probably continue to emerge, widespread immunity provides sustained protection against severe illness. Continued epidemiological surveillance remains vital to track the shift towards endemicity, detect seasonal patterns, and identify emerging variants, thereby informing future immunisation policies. In the long term, COVID-19 vaccination should be embedded into routine healthcare programmes across all stages of life. Furthermore, monitoring the co-circulation of COVID-19 with other respiratory pathogens is necessary to prevent concurrent infection peaks from overwhelming healthcare facilities. Addressing booster fatigue and vaccine hesitancy will require improved public education and the development of effective, combined vaccines targeting multiple respiratory threats.
As the immediate crisis of the pandemic recedes, managing COVID-19 requires sustainable public health strategies rather than emergency measures. Integrating vaccination into routine healthcare, tracking seasonal shifts alongside other respiratory viruses, and introducing combination vaccines will protect hospital capacity, reduce severe illness, and support long-term disease management without exhausting public willingness to receive boosters.
The findings highlight an applied development opportunity for pharmaceutical manufacturers and diagnostic developers to create effective, combined vaccines targeting COVID-19 alongside other respiratory viruses. Such multi-pathogen products, aimed at routine healthcare markets, could directly address booster fatigue and improve uptake. While the abstract does not assess specific formulations, it indicates an applied technological and market need for consolidated respiratory immunisation products.
AI-generated from the published abstract. Always read the original work before citing.
High population SARS-CoV-2 immunity indicates the likely end to the pandemic's acute phase. Continued emergence of variants/sublineages that can evade the vaccine-induced antibody response are likely, but widespread immunity reduces the risk of disease severity. Continued surveillance is required to capture transition to endemicity, seasonality, and emergence of novel variants/sublineages, to inform future vaccination strategies. COVID-19 vaccination should be integrated into routine vaccination programs throughout life. Co-circulation with other respiratory viruses should be monitored to avoid a combined peak, which could overrun healthcare systems. Effective, combined vaccines and improved education may help overcome vaccine hesitancy/booster fatigue and increase vaccination uptake.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/14760584.2024.2346589
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
